Acticor Biotech gets patent for cardiovascular emergency treatment product

French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036.

The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both of which also protect glenzocimab until 2036ell. The patent is also under examination in other countries such as Japan.

To date, three patent families, including four granted patents and 33 pending patent applications, protect glenzocimab and its therapeutic use. read more

stem cells

Research Shows Stem Cells Might Become a Game Changer for Multiple Sclerosis

Multiple sclerosis, an unpredictable neurodegenerative disease that impacts the brain and spinal cord, has been an enigma for researchers for years. Despite first being identified in the late 1800s, scientists are still scratching their heads about what causes the disease.

The Tisch Multiple Sclerosis Research Center of New York has been working toward finding the cause and a cure for MS since it first launched in 2006. The Center’s director and chief research scientist, Dr. Saud Sadiq, M.D., has been working toward finding the cause of the disease for over two decades. read more

Human Embryo

Controversial New Guidelines Would Allow Experiments On More Mature Human Embryos

For decades, scientists have been prohibited from keeping human embryos alive in their labs for more than 14 days. The prohibition was aimed at avoiding a thicket of ethical issues that would be raised by doing experiments on living human embryos as they continue to develop. But on Wednesday, an influential scientific society recommended scrapping that blanket taboo, known as the “14-day rule.”

Read more…

Biotech 3

Biotech Emerges as ‘Superhero’ of Global Pandemic

The global coronavirus pandemic is spurring a boom in health care investments, as companies large and small try to combat the infectious disease. Biotechs, in particular, have seen a boom in interest, as investors look to bet on what could be the next Moderna (MRNA).

Kedar Karkare, a health-care analyst at CB Insights, said 2020 was a record year for the sector.

“We had almost $42 billion invested into biopharmaceutical companies … across 1,851 deals,” Karkare said. That’s a 46% increase over 2019, but the number of deals was only 4% more than in 2019, indicating that more capital was spent making these deals, Karkare said.


Read more…

Female Biotechnician

Bharat Biotech’s Covaxin may provide Covid-19 immunity for 12 months

All India Institute of Medical Sciences (AIIMS) said that Bharat Biotech’s Covid-19 vaccine, Covaxin, may provide immunity against the disease for nine to 12 months, as per the mathematical calculations.

Covaxin’s approval in India faced criticism, especially when used for inoculating healthcare workers during Phase I of the vaccination drive, IANS reported.

The vaccine approval came even before the release of Phase III trial data.

IANS quoted AIIMS Bhopal and Jammu president YK Gupta as saying: “Covaxin was approved for emergency use and the data from Phase I and Phase II trials, and the ongoing Phase III trials, suggest that it is safe and effective, and by March-end tentatively, the data from Phase III trials will be available to establish its efficacy.”

“The vaccine is being given to lakhs of people, and there are hardly any serious side-effects. No death has been caused by Covaxin so far.”

A drug regulator gives approval if the efficacy of the drug is more than 50%, which was the case for Covaxin.

Read more….


Video: ‘Science Over Unjustified Cautiousness:’ Why UK Should Abandon Europe’s Biotech Crop Rules


Read more…

Biotech Coronavirus

The Pandemic Hasn’t Slowed Hiring at Local Biotech and Tech Companies

What does it mean to be part of the “quaranteam?”

If you got hired last year at Constellation Pharmaceuticals, but no one has yet met you face-to-face, you’re on it.

The Cambridge company is developing an array of drugs to treat cancer, and it hired about 75 people over the course of 2020. Brenda Sousa, chief human resources officer, says she expects this year’s hiring to run at about the same rate. But as the quaranteam has grown, the company has been increasingly open to hiring people outside of Massachusetts, Sousa says; some will be expected to relocate as the pandemic wanes, but others will stay where they are “due to the nature of their roles.”

Read more…


2021 Biotech IPOs Get Off to a Roaring Start

The year is starting off with a number of biopharma and life sciences initial public offerings (IPOs). Last year was a record number of IPOs in the biotech industry, with 81 raising $13.5 billion. With this kind of a start, 2021 may be scorching.

TCR2 Therapeutics – The Cambridge, Mass. company announced pricing for its underwritten offering of 4,590,164 shares on January 20 of $30.50 per share. The company hopes to raise $140 million of common stock, which will be used to advance its clinical and earlier stage programs and for R&D, working capital and general corporate purposes. TCR2 is developing novel T-cell therapies for solid tumors and hematological cancers. Its T-cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) recognize and kill cancer cells by leveraging signaling from the entire TCR.

TC-210 is currently in a Phase I/II trial for mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. TC-110 is in a Phase I/II trial for CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

Read more…


With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge

The Nobel Prize got Wall Street’s attention. On Oct. 7, the Swedish Academy awarded 2020’s Nobel in chemistry to two scientists for the development of Crispr-Cas9—a molecular scissors that can find and edit almost any sequence in a cell’s DNA. The 2012 discovery by Emmanuelle Charpentier and Jennifer Doudna had been commercialized with rare speed, and the Nobel was a boost for three companies founded to develop Crispr gene-editing therapies: Crispr Therapeutics,Intellia Therapeutics,and Editas Medicine.The three gene-editing stocks have more than doubled in the past few months, reaching a total market value above $23 billion.

Medical Syringe & Vaccine

Biotech Companies Working on a COVID-19 Vaccine For Cats

A group of bio technology companies are currently developing a COVID-19 vaccine for cats.

The Italian startup Takis Biothech is partnering with Applied DNA Sciences, a company based in New York, to create a two-dose vaccine that will hopefully be administered to cats by the end of the year.